Amelioration of the therapeutic potential of gefitinib against breast cancer using nanostructured lipid carriers.

Aim: This study aimed to improve the delivery and therapeutic potential of gefitinib (GTB) against breast cancer by preparing GTB-loaded, nanostructured lipid carriers (GTB-NLCs). Materials & methods: Box-Behnken design was used for optimization and GTB was loaded into NLCs using ultrasonication. The GTB-NLCs were characterized using in vitro, ex vivo and in vivo studies. The anticancer efficacy of GTB-NLCs was evaluated using 3-(4,5-dimethythiazol-2-yl)-2,5-diphenyltetrazolium bromide cytotoxicity and flow cytometry on MCF-7 breast cancer cell lines. Results: Optimized GTB-NLCs were successfully characterized and demonstrated improved internalization and enhanced cytotoxicity compared with plain GTB. Gut permeation studies showed enhanced intestinal permeability, and pharmacokinetic analysis revealed 2.6-fold improvement in GTB oral bioavailability. Conclusion: GTB-NLCs effectively enhanced the therapeutic potential of GTB against breast cancer.

[1]  Durgaramani Sivadasan,et al.  A review of nanomaterials from synthetic and natural molecules for prospective breast cancer nanotherapy , 2023, Frontiers in Pharmacology.

[2]  Wajhul Qamar,et al.  Optimization of Gefitinib-Loaded Nanostructured Lipid Carrier as a Biomedical Tool in the Treatment of Metastatic Lung Cancer , 2023, Molecules.

[3]  G. Zayed,et al.  Gefitinib-loaded starch nanoparticles for battling lung cancer: Optimization by full factorial design and in vitro cytotoxicity evaluation , 2022, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[4]  S. Alkahtani,et al.  Amelioration of bioavailability through formulating and optimizing Azilsartan Entrapped nanostructured lipid carriers and its pharmacokinetic assessment , 2022, Journal of Drug Delivery Science and Technology.

[5]  H. Popli,et al.  Design-of-Experiments (DoE)-Assisted Fabrication of Quercetin-Loaded Nanoemulgel and Its Evaluation against Human Skin Cancer Cell Lines , 2022, Pharmaceutics.

[6]  G. Aggarwal,et al.  Gefitinib: An Updated Review of its Role in the Cancer Management, its Nanotechnological Interventions, Recent Patents and Clinical Trials. , 2022, Recent Patents on Anti-Cancer Drug Discovery.

[7]  I. Jaiyesimi,et al.  Therapeutic landscape of advanced HER2-positive breast cancer in 2022 , 2022, Medical Oncology.

[8]  S. Beg,et al.  Optimization and validation of stability indicating RP-HPLC method for the quantification of gefitinib in bulk drug and nanoformulations: An application towards in vitro and ex vivo performance evaluation , 2022, Arabian Journal of Chemistry.

[9]  Jian-Hua Fu,et al.  Efficacy of adjuvant chemotherapy on overall survival in patients with lymph node‐positive esophageal squamous cell carcinoma: Is oral chemotherapy promising? , 2022, Cancer medicine.

[10]  Dinesh Nyavanandi,et al.  Review on the Scale-Up Methods for the Preparation of Solid Lipid Nanoparticles , 2022, Pharmaceutics.

[11]  F. Alanazi,et al.  Engineered Nanoscale Lipid-Based Formulation as Potential Enhancer of Gefitinib Lymphatic Delivery: Cytotoxicity and Apoptotic Studies Against the A549 Cell Line , 2022, AAPS PharmSciTech.

[12]  Annu,et al.  Ribociclib Nanostructured Lipid Carrier Aimed for Breast Cancer: Formulation Optimization, Attenuating In Vitro Specification, and In Vivo Scrutinization , 2022, BioMed research international.

[13]  E. Cobain,et al.  Breast cancer management in 2021: A primer for the obstetrics and gynecology. , 2022, Best practice & research. Clinical obstetrics & gynaecology.

[14]  K. Anand,et al.  Preparation and Evaluation of Gefitinib Containing Nanoliposomal Formulation for Lung Cancer Therapy , 2022, BioNanoScience.

[15]  Yosif Almoshari,et al.  Nanostructured lipid carrier system: A compendium of their formulation development approaches, optimization strategies by quality by design, and recent applications in drug delivery , 2022, Nanotechnology Reviews.

[16]  D. Bhatt,et al.  Development of novel lipid matrix for improved sustained release effect of a hydrophilic drug via response surface methodology , 2021, Journal of Drug Delivery Science and Technology.

[17]  David J Brayden,et al.  Formulation strategies to improve the efficacy of intestinal permeation enhancers. , 2021, Advanced drug delivery reviews.

[18]  Mohammed Elmowafy,et al.  Nanostructured lipid carriers (NLCs) as drug delivery platform: Advances in formulation and delivery strategies , 2021, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society.

[19]  Ajazuddin,et al.  Design and optimization of curcumin loaded nano lipid carrier system using Box-Behnken design. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  J. Magaña,et al.  Non-Ionic Surfactants for Stabilization of Polymeric Nanoparticles for Biomedical Uses , 2021, Materials.

[21]  O. Cevik,et al.  Long chain fatty acids can form aggregates and affect the membrane integrity. , 2021, Colloids and surfaces. B, Biointerfaces.

[22]  Gautam Singhvi,et al.  Dermatokinetic assessment of luliconazole-loaded nanostructured lipid carriers (NLCs) for topical delivery: QbD-driven design, optimization, and in vitro and ex vivo evaluations , 2021, Drug Delivery and Translational Research.

[23]  Jeonghee Cho,et al.  Dual Inhibition of AKT and MEK Pathways Potentiates the Anti-Cancer Effect of Gefitinib in Triple-Negative Breast Cancer Cells , 2021, Cancers.

[24]  R. Parton,et al.  Key principles and methods for studying the endocytosis of biological and nanoparticle therapeutics , 2021, Nature Nanotechnology.

[25]  D. Acierno,et al.  The universal usefulness of stearic acid as surface modifier: applications to the polymer formulations and composite processing , 2021 .

[26]  M. El-Nabarawi,et al.  Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy: in-vitro optimization and ex-vivo assessment , 2021, Drug delivery.

[27]  Xiangrong Zhang,et al.  Development and evaluation of puerarin-loaded controlled release nanostructured lipid carries by central composite design , 2020, Drug development and industrial pharmacy.

[28]  Yuankai Shi,et al.  Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020) , 2020, Journal of Hematology & Oncology.

[29]  Bhupinder Singh,et al.  QbD-steered development of Biotin-Conjugated Nanostructured Lipid Carriers for Oral Delivery of Chrysin: Role of Surface Modification for Improving Biopharmaceutical Performance. , 2020, Colloids and surfaces. B, Biointerfaces.

[30]  Pankaj Kumar,et al.  Lipid-nanopotentiated combinatorial delivery of tamoxifen and sulforaphane: ex vivo, in vivo and toxicity studies. , 2020, Nanomedicine.

[31]  N. M. Raghavendra,et al.  Development of novel S PC-3 gefitinib lipid nanoparticles for effective drug delivery in breast cancer. Tissue distribution studies and cell cytotoxicity analysis , 2020 .

[32]  E. M. Danielsen,et al.  Intestinal permeation enhancers: Lessons learned from studies using an organ culture model. , 2020, Biochimica et biophysica acta. Biomembranes.

[33]  Steven Abbott,et al.  Solubility, similarity, and compatibility: A general-purpose theory for the formulator , 2020 .

[34]  A. Kadi,et al.  EGFR Inhibitor Gefitinib Induces Cardiotoxicity through the Modulation of Cardiac PTEN/Akt/FoxO3a Pathway and Reactive Metabolites Formation: In Vivo and In Vitro Rat Studies. , 2020, Chemical research in toxicology.

[35]  K. Kohli,et al.  PEGylated liposomes as an emerging therapeutic platform for oral nanomedicine in cancer therapy: in vitro and in vivo assessment , 2020 .

[36]  N. Dudhipala,et al.  Enhanced pharmacokinetic activity of Zotepine via nanostructured lipid carrier system in Wistar rats for oral application. , 2020, Pharmaceutical nanotechnology.

[37]  S. Mohan,et al.  Gefitinib loaded nanostructured lipid carriers: characterization, evaluation and anti-human colon cancer activity in vitro , 2020, Drug delivery.

[38]  Sajjad Karim,et al.  Nanoparticles-based drug delivery and gene therapy for breast cancer: recent advancements and future challenges. , 2019, Seminars in cancer biology.

[39]  Annu,et al.  Optimization of Nanostructured Lipid Carriers of Lurasidone Hydrochloride Using Box-Behnken Design for Brain Targeting: In Vitro and In Vivo Studies. , 2019, Journal of pharmaceutical sciences.

[40]  Bhupinder Singh,et al.  Resveratrol loaded functionalized nanostructured lipid carriers for breast cancer targeting: Systematic development, characterization and pharmacokinetic evaluation. , 2019, Colloids and surfaces. B, Biointerfaces.

[41]  R. B. Walker,et al.  Short Term Stability Testing of Efavirenz-Loaded Solid Lipid Nanoparticle (SLN) and Nanostructured Lipid Carrier (NLC) Dispersions , 2019, Pharmaceutics.

[42]  K. Kohli,et al.  Nanostructured Lipid Carriers for oral bioavailability enhancement of Exemestane: Formulation design, in vitro, ex vivo and in vivo studies. , 2019, Journal of pharmaceutical sciences.

[43]  F. Wang,et al.  Uniform carboxymethyl chitosan-enveloped Pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound. , 2019, Colloids and surfaces. B, Biointerfaces.

[44]  S. Majumdar,et al.  Curcumin-loaded Nanostructured Lipid Carriers for Ocular Drug Delivery: Design Optimization and Characterization. , 2018, Journal of drug delivery science and technology.

[45]  Vieri Piazzini,et al.  Nanostructured Lipid Carriers as Promising Delivery Systems for Plant Extracts: The Case of Silymarin , 2018, Applied Sciences.

[46]  R. Saha,et al.  Nanostructured lipid carriers for site-specific drug delivery. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[47]  N. Jawahar,et al.  Enhanced oral bioavailability of an antipsychotic drug through nanostructured lipid carriers. , 2018, International journal of biological macromolecules.

[48]  A. Ahad,et al.  Formulation and optimization of nanostructured lipid carriers to enhance oral bioavailability of telmisartan using Box–Behnken design , 2018 .

[49]  O. Abdallah,et al.  Novel cremochylomicrons for improved oral bioavailability of the antineoplastic phytomedicine berberine chloride: Optimization and pharmacokinetics. , 2018, International journal of pharmaceutics.

[50]  A. Beloqui,et al.  Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs , 2017 .

[51]  H. Mahajan,et al.  Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study , 2016, Drug delivery.

[52]  M. Blanco-Prieto,et al.  Cyclosporine A lipid nanoparticles for oral administration: Pharmacodynamics and safety evaluation. , 2016, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[53]  G. Zhai,et al.  Nanostructured lipid carriers for oral delivery of baicalin: In vitro and in vivo evaluation , 2015 .

[54]  V. Pokharkar,et al.  Montelukast-loaded nanostructured lipid carriers: part II pulmonary drug delivery and in vitro-in vivo aerosol performance. , 2014, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[55]  Han‐Gon Choi,et al.  Preparation and Characterization of Fenofibrate-Loaded Nanostructured Lipid Carriers for Oral Bioavailability Enhancement , 2014, AAPS PharmSciTech.

[56]  Swati S. Korabu,et al.  Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride. , 2014, Colloids and surfaces. B, Biointerfaces.

[57]  S. Nonen,et al.  Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity. , 2013, Clinical lung cancer.

[58]  M. Shahedi,et al.  Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food molecules , 2013 .

[59]  R. Tan,et al.  Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs? , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[60]  M. H. Santana,et al.  Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery , 2011, Journal of drug delivery.

[61]  R. Müller,et al.  Cyclosporine-loaded solid lipid nanoparticles (SLN): drug-lipid physicochemical interactions and characterization of drug incorporation. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.